Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma |
Van Andel Research Institute / Patrick Grohar, MD, PhD |
Reach Grants |
2013 |
Michigan |
Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL |
University of Colorado Denver / Doug Graham, MD, PhD |
Reach Grants |
2013 |
Colorado |
Development of a Connectedness with Healthcare Providers Scale for Adolescents and Young Adults with Cancer |
Indiana University / Celeste Phillips-Salimi |
Nurse Researcher Grants |
2011 |
Indiana |
Development of a comprehensive liquid biopsy-based genomics platform for pediatric solid tumors |
Children’s Hospital Los Angeles / Jaclyn Biegel |
Catalyst Grants |
2023 |
California |
Development of a childhood leukemia translational research program.
|
Dana-Farber Cancer Institute / Lewis Silverman |
Phase I/II Infrastructure Grants |
2009 |
Massachusetts |
Development of a Childhood Leukemia Translational Research Program |
Dana-Farber Cancer Institute / Lewis Silverman |
Phase I/II Infrastructure Grants |
2011 |
Massachusetts |
Development and Characterization of Novel Models of Human Osteosarcoma Development and Metastasis |
University of Minnesota / Beau Webber, PhD |
Young Investigator Grants |
2017 |
Minnesota |
Developing Targeted Immunotherapy Against Pediatric Acute Myeloid Leukemia |
Fred Hutchinson Cancer Research Center / Melinda Biernacki, MD |
Young Investigator Grants |
2016 |
Washington |
Developing Personalized (precision) Medicine Strategies to Optimize Pediatric Brain Tumor Management |
Washington University / David Gutmann, M.D., Ph.D. |
Innovation Grants |
2014 |
Missouri |
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia |
Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD |
Innovation Grants |
2022 |
New York |